Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914

Journal of Biological Chemistry

Volumn 290, Issue 34, 2015, Pages 20984-20994

  Kern, Gunther ^a   Palmer, Tiffany ^a   Ehmann, David E ^a   Shapiro, Adam B ^a   Andrews, Beth ^a   Basarab, Gregory S ^a   Doig, Peter ^a   Fan, Jun ^a   Gao, Ning ^a   Mills, Scott D ^a   Mueller, John ^a   Sriram, Shubha ^a   Thresher, Jason ^a   Walkup, Grant K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOCHEMISTRY; DNA; ENZYMES; ESCHERICHIA COLI; STABILIZATION;

ANTI-BACTERIAL ACTIVITY; ANTIBACTERIAL COMPOUNDS; BACTERIAL SPECIES; BACTERICIDAL ACTIVITY; MULTIDRUG RESISTANTS; NEISSERIA GONORRHOEAE; RESISTANT MUTANTS; TOPOISOMERASE IV;

ENZYME INHIBITION;

AMPICILLIN; ANTIINFECTIVE AGENT; AZD 0914; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; DNA TOPOISOMERASE IV; DOUBLE STRANDED DNA; ETOPOSIDE; GYRASE INHIBITOR; NOVOBIOCIN; UNCLASSIFIED DRUG; BACTERIAL DNA; BARBITURIC ACID DERIVATIVE; DNA; QUINOLONE DERIVATIVE; SPIRO COMPOUND; ZOLIFLODACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA PROTEIN COMPLEX; DNA REPAIR; DNA SUPERCOILING; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ESCHERICHIA COLI; IC50; MACROMOLECULE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MUTATION; SPECIES DIFFERENCE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; NEISSERIA GONORRHOEAE; POSIBACTERIA;

ANTI-BACTERIAL AGENTS; BARBITURATES; CIPROFLOXACIN; CLINICAL TRIALS AS TOPIC; DNA; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; GENE EXPRESSION; HUMANS; MUTATION; NEISSERIA GONORRHOEAE; SPECIES SPECIFICITY; SPIRO COMPOUNDS; TOPOISOMERASE II INHIBITORS;

EID: 84939864397     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.663534     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention (2013) Antibiotic Resistance Threats in the United States, 2013, United States Department of Health and Human Resources, Washington, D. C.
2. Centers for Disease Control and Prevention (2013) Neisseria gonorrhoeae infection frequency in the U.S.A., United States Department of Health and Human Resources, Washington, D. C.
3. Lowndes, C. (2014) Update from the Health Protection Agency: Update on Resistance of Neisseria gonorrhoeae to Antimicrobials, Health Protection Agency, London
4. Jacobsson, S., Golparian, D., Alm, R. A., Huband, M., Mueller, J., Jensen, J. S., Ohnishi, M., and Unemo, M. (2014) High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob. Agents Chemother. 58, 5585-5588
5. Emami, S., Shafiee, A., and Foroumadi, A. (2006) Structural features of new quinolones and relationship to antibacterial activity against Grampositive bacteria. Mini Rev. Med. Chem. 6, 375-386
6. Mitscher, L. A. (2005) Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev. 105, 559-592
7. Maxwell, A. (1997) DNA gyrase as a drug target. Trends Microbiol. 5, 102-109
8. Maxwell, A. (1999) DNA gyrase as a drug target. Biochem. Soc. Trans. 27, 48-53
9. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., and Tomizawa, J. I. (1977) Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. U.S.A. 74, 4772-4776
10. Hilliard, J. J., Goldschmidt, R. M., Licata, L., Baum, E. Z., and Bush, K. (1999) Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob. Agents Chemother 43, 1693-1699
11. Maxwell, A., and Lawson, D. M. (2003) The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 3, 283-303
12. Chu, D. T., Hallas, R., Clement, J. J., Alder, J., McDonald, E., and Plattner, J. J. (1992) Synthesis and antitumour activities of quinolone antineoplastic agents. Drugs Exp. Clin. Res. 18, 275-282
13. Hoshino, K., Sato, K., Une, T., and Osada, Y. (1989) Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob. Agents Chemother. 33, 1816-1818
14. Roca, J., Berger, J. M., Harrison, S. C., and Wang, J. C. (1996) DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism. Proc. Natl. Acad. Sci. U.S.A. 93, 4057-4062
15. Roca, J., and Wang, J. C. (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71, 833-840
16. Roca, J., and Wang, J. C. (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77, 609-616
17. Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X. S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 16, 667-669
18. Ehmann, D. E., and Lahiri, S. D. (2014) Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. Curr. Opin. Pharmacol. 18, 76-83
19. Wiener, J. J., Gomez, L., Venkatesan, H., Santillán, A., Jr., Allison, B. D., Schwarz, K. L., Shinde, S., Tang, L., Hack, M. D., Morrow, B. J., Motley, S. T., Goldschmidt, R. M., Shaw, K. J., Jones, T. K., and Grice, C. A. (2007) Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. Bioorg. Med. Chem. Lett. 17, 2718-2722
20. Shapiro, A., Jahic, H., Prasad, S., Ehmann, D., Thresher, J., Gao, N., and Hajec, L. (2010) A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay. J. Biomol. Screen 15, 1088-1098
21. Basarab, G. S., Brassil, P., Doig, P., Galullo, V., Haimes, H. B., Kern, G., Kutschke, A., McNulty, J., Schuck, V. J., Stone, G., and Gowravaram, M. (2014) Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization. J. Med. Chem. 57, 9078-9095
22. Patrzykat, A., Friedrich, C. L., Zhang, L., Mendoza, V., and Hancock, R. E. (2002) Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob. Agents Chemother. 46, 605-614
23. Fan, J., de Jonge, B. L., MacCormack, K., Sriram, S., McLaughlin, R. E., Plant, H., Preston, M., Fleming, P. R., Albert, R., Foulk, M., and Mills, S. D. (2014) A novel high-throughput cell-based assay aimed at identifying inhibitors of DNA metabolism in bacteria. Antimicrob. Agents Chemother. 58, 7264-7272
24. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
25. Mizuuchi, K., Mizuuchi, M., and Craigie, R. (1984) The mechanism of transposition of bacteriophage μ. Cold Spring Harb. Symp. Quant. Biol. 49, 835-838
26. Gellert, M., Fisher, L. M., and O'Dea, M. H. (1979) DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein. Proc. Natl. Acad. Sci. U.S.A. 76, 6289-6293
27. Pierrat, O. A., and Maxwell, A. (2003) The action of the bacterial toxin microcin B17. Insight into the cleavage-religation reaction of DNA gyrase. J. Biol. Chem. 278, 35016-35023
28. nd Ed., Methuen, London, UK
29. Martell, A. E., and Smith, R. M. (2001) NIST Critical Stability Constants of Metal Complexes, National Institute of Standards and Technology, Gaithersburg, MD
30. Shapiro, A. B. (2013) A high-throughput-compatible, fluorescence anisotropy-based assay for ATP-dependent supercoiled DNA relaxation by human topoisomerase IIα. Biochem. Pharmacol. 85, 1269-1277
31. Shapiro, A. B., and Austin, C. A. (2014) A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation. Anal. Biochem. 448, 23-29
32. Schlacher, K., Cox, M. M., Woodgate, R., and Goodman, M. F. (2006) RecA acts in trans to allow replication of damaged DNA by DNA polymerase V. Nature 442, 883-887
33. Schlacher, K., Pham, P., Cox, M. M., and Goodman, M. F. (2006) Roles of DNA polymerase V and RecA protein in SOS damage-induced mutation. Chem. Rev. 106, 406-419
34. Janion, C. (2008) Inducible SOS response system of DNA repair and mutagenesis in Escherichia coli. Int. J. Biol. Sci. 4, 338-344
35. Huband, M. D., Bradford, P. A., Otterson, L. G., Basarab, G. S., Kutschke, A. C., Giacobbe, R. A., Patey, S. A., Alm, R. A., Johnstone, M. R., Potter, M. E., Miller, P. F., and Mueller, J. P. (2015) In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob. Agents Chemother. 59, 467-474
36. Palú, G., Valisena, S., Ciarrocchi, G., Gatto, B., and Palumbo, M. (1992) Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. U.S.A. 89, 9671-9675
37. Aldred, K. J., Breland, E. J., McPherson, S. A., Turnbough, C. L., Jr., Kerns, R. J., and Osheroff, N. (2014) Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge. Antimicrob. Agents Chemother. 58, 7182-7187
38. Aldred, K. J., McPherson, S. A., Turnbough, C. L., Jr., Kerns, R. J., and Osheroff, N. (2013) Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 41, 4628-4639
39. Alm, R. A., Lahiri, S. D., Kutschke, A., Otterson, L. G., McLaughlin, R. E., Whiteaker, J. D., Lewis, L. A., Su, X., Huband, M. D., Gardner, H., and Mueller, J. P. (2015) Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 59, 1478-1486
40. Endimiani, A., Guilarte, Y. N., Tinguely, R., Hirzberger, L., Selvini, S., Lupo, A., Hauser, C., and Furrer, H. (2014) Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998-2012): emergence of multidrug-resistant clones less susceptible to cephalosporins. BMC Infect. Dis. 14, 106
41. Belland, R. J., Morrison, S. G., Ison, C., and Huang, W. M. (1994) Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. 14, 371-380
42. Deguchi, T., Yasuda, M., Nakano, M., Ozeki, S., Kanematsu, E., Fukuda, H., Maeda, S., Saito, I., and Kawada, Y. (1997) Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. Chemotherapy 43, 239-244
43. Aldred, K. J., Kerns, R. J., and Osheroff, N. (2014) Mechanism of quinolone action and resistance. Biochemistry 53, 1565-1574
44. Wohlkonig, A., Chan, P. F., Fosberry, A. P., Homes, P., Huang, J., Kranz, M., Leydon, V. R., Miles, T. J., Pearson, N. D., Perera, R. L., Shillings, A. J., Gwynn, M. N., and Bax, B. D. (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 17, 1152-1153
45. Aldred, K. J., Schwanz, H. A., Li, G., McPherson, S. A., Turnbough, C. L., Jr., Kerns, R. J., and Osheroff, N. (2013) Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem. Biol. 8, 2660-2668
46. Segev, S., Yaniv, I., Haverstock, D., and Reinhart, H. (1999) Safety of longterm therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin. Infect. Dis. 28, 299-308
47. Cambau, E., Matrat, S., Pan, X. S., Roth Dit Bettoni, R., Corbel, C., Aubry, A., Lascols, C., Driot, J. Y., and Fisher, L. M. (2009) Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli. J. Antimicrob. Chemother. 63, 443-450
48. Shultz, T. R., Tapsall, J. W., and White, P. A. (2001) Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob. Agents Chemother. 45, 734-738
49. Khodursky, A. B., and Cozzarelli, N. R. (1998) The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273, 27668-27677
50. Aedo, S., and Tse-Dinh, Y. C. (2012) Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA. Antimicrob. Agents Chemother. 56, 5458-5464
51. Anderson, V. E., Zaniewski, R. P., Kaczmarek, F. S., Gootz, T. D., and Osheroff, N. (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV: changes in drug mechanism across evolutionary boundaries. J. Biol. Chem. 274, 35927-35932
52. Aldred, K. J., McPherson, S. A., Wang, P., Kerns, R. J., Graves, D. E., Turnbough, C. L., Jr., and Osheroff, N. (2012) Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry 51, 370-381